Estados financieros detallados de Pharvaris N.V. (PHVS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $37.55, PHVS presenta beneficios negativos (P/E no significativo) y un ROE del -61.24%. La capitalización bursátil es de $2.6B.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | $614 | $8437 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | -$614 | -$8437 | 0 | 0 | 0 | 0 | 0 |
| I+D | $3.6M | $6.4M | $22.2M | $35.8M | $57.4M | $65.6M | $98.6M | $124.5M |
| Generales y Administrativos | $668121 | $2.6M | $6.3M | $18.3M | $29.3M | $31.3M | $47.1M | $45.3M |
| Gastos Operativos | $4.3M | $9.0M | $28.5M | $54.1M | $86.7M | $96.9M | $145.7M | $169.8M |
| Beneficio Operativo | -$4.3M | -$9.0M | -$28.5M | -$54.1M | -$86.7M | -$96.9M | -$145.7M | -$169.8M |
| EBITDA | -$4.3M | -$9.0M | -$29.7M | -$42.3M | -$86.6M | -$99.6M | -$145.6M | -$173.3M |
| Gastos por Intereses | 0 | 0 | $92470 | $278181 | $16105 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$4.3M | -$9.0M | -$29.7M | -$42.7M | -$75.7M | -$99.8M | -$132.4M | -$173.7M |
| Impuestos | $380 | 0 | -$94904 | $70117 | $679087 | $1.0M | $1.8M | $2.0M |
| Beneficio Neto | -$4.3M | -$9.0M | -$29.6M | -$42.7M | -$76.3M | -$100.9M | -$134.2M | -$175.7M |
| BPA | $-0.14 | $-0.25 | $-0.85 | $-1.41 | $-2.27 | $-2.63 | $-2.48 | $-2.97 |
| BPA Diluido | $-0.14 | $-0.25 | $-0.85 | $-1.41 | $-2.27 | $-2.63 | $-2.48 | $-2.97 |
| Acciones en Circulación (Diluidas) | $31.8M | $31.8M | $30.5M | $30.4M | $33.6M | $38.4M | $54.0M | $59.2M |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $4.8M | $5.4M | $20.3M | $98.6M | $209.4M | $161.8M | $391.2M | $280.7M | $291.7M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $1056 | 0 | $210843 | $569578 | $700079 | $382468 | $1.0M | $2.9M | $4.6M |
| Inventario | 0 | 0 | 0 | 0 | 0 | $4.0M | 0 | 0 | 0 |
| Activos Corrientes | $4.8M | $5.4M | $20.6M | $101.0M | $211.6M | $166.8M | $397.9M | $289.4M | $299.2M |
| Inmovilizado Material | 0 | 0 | $12927 | $48503 | $351349 | $626439 | $455571 | $1.5M | $1.4M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $4.8M | $5.4M | $20.6M | $101.1M | $212.1M | $167.7M | $398.7M | $291.4M | $301.5M |
| Cuentas por Pagar | $60472 | $246356 | $517771 | $656448 | $2.1M | $6.0M | $2.9M | $4.6M | $5.1M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $138836 | $481340 | $1.9M | $5.3M | $7.0M | $18.2M | $14.6M | $23.0M | $29.6M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $138836 | $481340 | $1.9M | $5.3M | $7.1M | $18.5M | $14.6M | $23.6M | $30.2M |
| Reservas | -$6.1M | -$10.4M | -$18.5M | -$44.5M | -$87.6M | -$164.2M | -$265.9M | -$402.3M | -$579.6M |
| Patrimonio Neto | $4.7M | $5.0M | $18.7M | $95.8M | $205.0M | $149.3M | $384.0M | $267.8M | $271.3M |
| Deuda Total | 0 | 0 | 0 | 0 | $250184 | $436822 | $238905 | $861470 | $776798 |
| Deuda Neta | -$4.8M | -$5.4M | -$20.3M | -$98.6M | -$209.1M | -$161.4M | -$391.0M | -$279.9M | -$290.9M |
| Capital Circulante | $4.7M | $5.0M | $18.7M | $95.6M | $204.6M | $148.6M | $383.2M | $266.4M | $269.6M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$4.3M | -$8.0M | -$26.1M | -$42.7M | -$75.7M | -$99.8M | -$132.4M | -$173.7M |
| Amortizaciones | 0 | $549 | $7401 | $77370 | $152941 | $257551 | $269562 | $418353 |
| Compensación en Acciones | $100745 | $116147 | $1.6M | $8.2M | $11.3M | $10.7M | $16.2M | $19.1M |
| Cambio en Capital Circulante | $291547 | $1.2M | $1.6M | $1.6M | $8.4M | -$5.9M | $5.9M | $7.6M |
| Flujo de Caja Operativo | -$3.9M | -$6.7M | -$21.5M | -$44.6M | -$67.2M | -$93.0M | -$120.1M | -$137.1M |
| Inversiones (CapEx) | 0 | -$13476 | -$42977 | -$130032 | -$124296 | -$89984 | -$538086 | -$164619 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$3.9M | -$6.7M | -$21.5M | -$44.7M | -$67.3M | -$93.1M | -$120.7M | -$137.2M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -108.2% | -229.7% | -44.2% | -78.6% | -32.2% | -33.1% | -30.9% | |
| Crecimiento BPA (anual) | -78.6% | -240.0% | -65.9% | -61.0% | -15.9% | +5.7% | -19.8% | |
| Cambio en Acciones (anual) | +0.0% | -4.1% | -0.4% | +10.4% | +14.3% | +40.7% | +9.5% | |
| Crecimiento FCF (anual) | -70.7% | -222.0% | -107.6% | -50.4% | -38.4% | -29.6% | -13.7% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | 0.3% | -0.2% | -0.9% | -1.1% | -1.4% | -1.1% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.12 | $-0.21 | $-0.71 | $-1.47 | $-2.00 | $-2.43 | $-2.23 | $-2.32 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $31.8M | $31.8M | $30.5M | $30.4M | $33.6M | $38.4M | $54.0M | $59.2M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -61.24% |
| Rentabilidad sobre capital invertido | -60.72% |
| Rentabilidad sobre activos | -52.20% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 11.94 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| P/E | 0.00 | -180.63 | -103.44 | -27.92 | -8.97 | -4.63 | -9.65 | -7.46 | -7.95 |
| P/VC | 0.00 | 162.56 | 44.09 | 7.56 | 1.88 | 2.36 | 2.54 | 3.73 | 5.15 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ARDX · BCRX · IMNM · MAZE · NTLA · ORIC · SYRE
Explorar sector: Healthcare · Biotechnology
Más secciones de PHVS: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones